Cargando…

Influence of Genetic Variation in COMT on Cisplatin-Induced Nephrotoxicity in Cancer Patients

Cisplatin is a chemotherapeutic agent widely used for multiple indications. Unfortunately, in a substantial set of patients treated with cisplatin, dose-limiting acute kidney injury (AKI) occurs. Here, we assessed the association of 3 catechol-O-methyltransferase (COMT) single nucleotide polymorphis...

Descripción completa

Detalles Bibliográficos
Autores principales:	Agema, Bram C., Koolen, Stijn L.W., de With, Mirjam, van Doorn, Nadia, Heersche, Niels, Oomen-de Hoop, Esther, Visser, Sabine, Aerts, Joachim G.J.V., Bins, Sander, van Schaik, Ron H.N., Mathijssen, Ron H.J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7230333/ https://www.ncbi.nlm.nih.gov/pubmed/32230800 http://dx.doi.org/10.3390/genes11040358

Ejemplares similares

Irinotecan-Induced Toxicity: A Pharmacogenetic Study Beyond UGT1A1
por: de With, Mirjam, et al.
Publicado: (2023)

Association between single-nucleotide polymorphisms and adverse events in nivolumab-treated non-small cell lung cancer patients
por: Bins, Sander, et al.
Publicado: (2018)

Feasibility of Extrapolating Randomly Taken Plasma Samples to Trough Levels for Therapeutic Drug Monitoring Purposes of Small Molecule Kinase Inhibitors
por: van Eerden, Ruben A. G., et al.
Publicado: (2021)

Tissue Type Differences in ABCB1 Expression and Paclitaxel Tissue Pharmacokinetics in Patients With Esophageal Cancer
por: van Eerden, Ruben A. G., et al.
Publicado: (2021)

Population Pharmacokinetics of Oxycodone and Metabolites in Patients with Cancer-Related Pain
por: Agema, Bram C., et al.
Publicado: (2021)

Germline Variation in PDCD1 Is Associated with Overall Survival in Patients with Metastatic Melanoma Treated with Anti-PD-1 Monotherapy
por: de With, Mirjam, et al.
Publicado: (2021)

Influence of aprepitant and localization of the patch on fentanyl exposure in patients with cancer using transdermal fentanyl
por: Kuip, Evelien J.M., et al.
Publicado: (2018)

Granzyme B is correlated with clinical outcome after PD-1 blockade in patients with stage IV non-small-cell lung cancer
por: Hurkmans, Daan P., et al.
Publicado: (2020)

Influence of germline variations in drug transporters ABCB1 and ABCG2 on intracerebral osimertinib efficacy in patients with non-small cell lung cancer
por: Veerman, G.D. Marijn, et al.
Publicado: (2023)

Efficacy and Toxicity of Weekly Carboplatin and Paclitaxel as Induction or Palliative Treatment in Advanced Esophageal Cancer Patients
por: de Man, Femke M., et al.
Publicado: (2019)

Influence of Probenecid on the Pharmacokinetics and Pharmacodynamics of Sorafenib
por: Hussaarts, Koen G. A. M., et al.
Publicado: (2020)

Dietary sodium restriction prevents vascular endothelial growth factor inhibitor-induced hypertension
por: van Doorn, Leni, et al.
Publicado: (2022)

Effects of smoking and body mass index on the exposure of fentanyl in patients with cancer
por: Kuip, Evelien J. M., et al.
Publicado: (2018)

Prognostic factors in men with metastatic castration-resistant prostate cancer treated with cabazitaxel
por: Belderbos, Bodine P.S., et al.
Publicado: (2017)

Combining Sorafenib and Immunosuppression in Liver Transplant Recipients with Hepatocellular Carcinoma
por: Hussaarts, Koen G. A. M., et al.
Publicado: (2021)

Pharmacokinetics of Sublingually Delivered Fentanyl in Head and Neck Cancer Patients Treated with Curatively Aimed Chemo or Bioradiotherapy
por: Kuip, Evelien J. M., et al.
Publicado: (2018)

The Influence of Body Composition on the Systemic Exposure of Paclitaxel in Esophageal Cancer Patients
por: van Doorn, Leni, et al.
Publicado: (2021)

Individualization of Irinotecan Treatment: A Review of Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics
por: de Man, Femke M., et al.
Publicado: (2018)

A prospective cohort study on the pharmacokinetics of nivolumab in metastatic non-small cell lung cancer, melanoma, and renal cell cancer patients
por: Hurkmans, Daan P., et al.
Publicado: (2019)

Effect of Scalp Cooling on the Pharmacokinetics of Paclitaxel
por: van Doorn, Leni, et al.
Publicado: (2021)

CYP3A4*22 Genotype-Guided Dosing of Kinase Inhibitors in Cancer Patients
por: van Eerden, Ruben A. G., et al.
Publicado: (2023)

Influence of probenecid on endoxifen systemic exposure in breast cancer patients on adjuvant tamoxifen treatment
por: Buck, Stefan A. J., et al.
Publicado: (2022)

Impact of Curcumin (with or without Piperine) on the Pharmacokinetics of Tamoxifen
por: Hussaarts, Koen G.A.M., et al.
Publicado: (2019)

CYP3A4(∗)22 Genotyping in Clinical Practice: Ready for Implementation?
por: Mulder, Tessa A. M., et al.
Publicado: (2021)

Impact of CYP3A4*22 on Pazopanib Pharmacokinetics in Cancer Patients
por: Bins, Sander, et al.
Publicado: (2018)

Clinical Application of Pharmacogenetics: Where are We Now?
por: van Schaik, Ron HN
Publicado: (2014)

Recent Clinical Developments of Nanomediated Drug Delivery Systems of Taxanes for the Treatment of Cancer
por: van Eerden, Ruben A G, et al.
Publicado: (2020)

Prospective real-world study on the pharmacokinetics of pembrolizumab in patients with solid tumors
por: Hurkmans, Daan P., et al.
Publicado: (2021)

Plasma Predictive Features in Treating EGFR-Mutated Non-Small Cell Lung Cancer
por: Steendam, Christi M. J., et al.
Publicado: (2020)

Docetaxel Skin Exposure and Micronucleation Contributes to Skin Toxicity Caused by CPC634
por: Atrafi, Florence, et al.
Publicado: (2021)

6. Dose Adjustments Based on Pharmacogenetics of CYP450 Enzymes
por: van Schaik, Ron H.N.
Publicado: (2008)

Improving the tolerability of osimertinib by identifying its toxic limit
por: Agema, Bram C., et al.
Publicado: (2022)

Treatment and Implications of Vascular Endothelial Growth Factor Inhibitor‐Induced Blood Pressure Rise: A Clinical Cohort Study
por: van Dorst, Daan C. H., et al.
Publicado: (2022)

Influence of green tea consumption on endoxifen steady-state concentration in breast cancer patients treated with tamoxifen
por: Braal, C. Louwrens, et al.
Publicado: (2020)

Blood-based extracellular matrix biomarkers are correlated with clinical outcome after PD-1 inhibition in patients with metastatic melanoma
por: Hurkmans, Daan P, et al.
Publicado: (2020)

Therapeutic Drug Monitoring of Endoxifen for Tamoxifen Precision Dosing: Feasible in Patients with Hormone-Sensitive Breast Cancer
por: Braal, C. Louwrens, et al.
Publicado: (2021)

Factors affecting inter-individual variability in endoxifen concentrations in patients with breast cancer: results from the prospective TOTAM trial
por: Braal, C. Louwrens, et al.
Publicado: (2022)

Clinical CYP2D6 Genotyping to Personalize Adjuvant Tamoxifen Treatment in ER-Positive Breast Cancer Patients: Current Status of a Controversy
por: Mulder, Tessa A. M., et al.
Publicado: (2021)

Cardiac Toxicity of Alectinib in Patients With ALK+ Lung Cancer: Outcomes of Cardio-Oncology Follow-Up
por: Pruis, Melinda A., et al.
Publicado: (2023)

Influence of the Proton Pump Inhibitor Esomeprazole on the Bioavailability of Regorafenib: A Randomized Crossover Pharmacokinetic Study
por: de Man, Femke M., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_kagugho0djnce6snkkm1hu4h2t